35 results on '"Gehrs, Leah"'
Search Results
2. Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation
3. A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease
4. CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells
5. Targeting CXCR4, VLA-4, and CXCR2 for hematopoietic stem cell mobilization
6. A mouse model of Zhu-Tokita-Takenouchi-Kim syndrome reveals indispensable SON functions in organ development and hematopoiesis
7. A mouse model of ZTTK syndrome reveals indispensable SON functions in organ development and hematopoiesis
8. Duvelisib for Critically Ill Patients With Coronavirus Disease 2019: An Investigator-Initiated, Randomized, Placebo-Controlled, Double-Blind Pilot Trial
9. POSTER: AML-080 Modeling Flotetuzumab-Associated Cytokine Release Syndrome (CRS) in AML Using In Vitro and In Vivo Preclinical Models
10. AML-080 Modeling Flotetuzumab-Associated Cytokine Release Syndrome (CRS) in AML Using In Vitro and In Vivo Preclinical Models
11. Continuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cells
12. An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
13. Data from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
14. Table S5 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
15. Supplementary Figures from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
16. Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
17. Modeling Flotetuzumab-Associated CRS in AML Using in Vitro and in Vivo Preclinical Models
18. Optimized Small Molecule VLA-4 Inhibitors for Hematopoietic Stem and Progenitor Cell Mobilization
19. Re-Sensitization of Allogeneic T Cell Resistant Murine AML with Pegylated IFN-Gamma
20. A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
21. A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
22. Novel Small Molecule VLA-4 Inhibitors Optimized for Extended Hematopoietic and Progenitor Cell Mobilization
23. A Mouse Model of Zhu-Tokita-Takenouchi-Kim Syndrome Reveals Indispensable Son Functions in Myeloid-Lymphoid Lineage Balance and Terminal Differentiation
24. Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation
25. A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes
26. Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma
27. Abstract 5699: AMV564, a bivalent, bispecific T-cell engager, depletes myeloid-derived suppressor cells and activates T cells in cancer patients
28. Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post–allogeneic hematopoietic stem cell transplant patient
29. Modeling Flotetuzumab-Associated CRS in AML Using inVitro and inVivo Preclinical Models
30. 386 - A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
31. Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells
32. #15. Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma.
33. An Off-the-Shelf™ Fratricide-Resistant CAR-T for the Treatment of T Cell Hematologic Malignancies
34. Modeling Flotetuzumab-Associated CRS in AML Using inVitroand inVivoPreclinical Models
35. A mouse model of ZTTK syndrome reveals indispensable SON functions in organ development and hematopoiesis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.